Skip to main content
Article thumbnail
Location of Repository

Screening and Identification of MicroRNAs Related to Acquired Gefitinib-resistance 
in Lung Adenocarcinoma Cell Lines

By Xuebo QIN, Bin LIU, Yang LI, Jiacong YOU and Qinghua ZHOU

Abstract

Background and objective Acquired gefitinib-resistance was closely related to inefficiency of EGFR-TKI treatment in lung adenocarcinoma. However, it was not clear that how microRNAs influenced the acquired gefitinib-resistance in lung adenocarcinoma. The aim of this study is to screen and identify the microRNAs correlated with the acquired gefitinib -resistance in lung adenocarcinoma. Methods Morphological difference was observed in gefitinib-sensitive lung adenocarcinoma cell line PC9 cell line and gefitinib-resistance lung adenocarcinoma cell line PC9/AB11 cell line derived from PC9 cell line. Cell cycles and doubling time were detected by flow cytometry, IC50 of gefitinib was evaluated by MTT assay. The differential microRNAs related to acquired gefitinib-resistance were screened and identified by microRNA array and real-time PCR. Results There were obvious morphological differences between PC9 and PC9/AB11 cells. The doubling time, distribution of cell cycle, and the IC50 between PC9 and PC9/AB11 were significantly different. In microarray analysis, compared with PC9 cell line, 4 up-regulated microRNAs were found in PC9/AB11 cells, 9 down-regulated microRNAs were found in PC9/AB11 cells. Real-time PCR revealed that miR-138 was significantly down-regulated in PC9/AB11 cells, accord with the microarray. Conclusion MicroRNAs are involved in acquired Gefitinib-resistance of lung adenocarcinoma. Our data presented here to provide an experimental basis and theory thereunder for further study of effect and molecule mechanism underlying the acquired gefitinib-resistance of lung cancer

Topics: Lung neoplasms, microRNAs, Gefitinib, Aquired-resistance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Internal medicine, RC31-1245, Medicine, R, DOAJ:Oncology, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: Chinese Anti-Cancer Association; Chinese Antituberculosis Association
Year: 2011
DOI identifier: 10.3779/j.issn.1009-3419.2011.06.18
OAI identifier: oai:doaj.org/article:ee8cc5aa3bf84af38471f6cd6fa86de4
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1999-6187 (external link)
  • https://doaj.org/toc/1009-3419 (external link)
  • http://dx.doi.org/10.3779/j.is... (external link)
  • https://doaj.org/article/ee8cc... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.